The company is developing a drug to treat traumatic brain injury using a molecule extracted from marine macroalgae. This molecule targets the immune system to promote repair after brain trauma. The therapy aims to reduce stimulate the immune cells and enhance neurological recovery. We also work to valorise extraction by-products, ensuring a sustainable, biotech-driven approach to neurorepair. Expertise is sought in polysaccharide chemistry and extraction of molecules at pharmaceutical grade.
Ref.RDRMD20260622006.Un hospital terciario de Moldavia con cepas resistentes a los antimicrobianos busca socios de I+D para el programa Horizonte Europa(HORIZON-HLTH-2027-01-DISEASE-08).
A tertiary hospital in the Republic of Moldova, with about 30 clinical departments, 772 beds and an active clinical microbiology laboratory, seeks R&D partners for Horizon Europe call HORIZON-HLTH-2027-01-DISEASE-08 on innovative antimicrobials. The hospital...
Jun 25, 2026















